Company Announcements

Spire Healthcare Group plc

("Spire Healthcare", "the Company" or "the Group")

Heads of Terms signed with the NHS in Wales to provide COVID-19 support

6 April 2020

Spire Healthcare (LSE: SPI), a leading UK independent hospital group, can confirm it has signed Heads of Terms with the Welsh Health Specialised Services Committee to make its facilities and services available to the NHS and its patients during the COVID-19 outbreak. This agreement, which commences on Monday 6 April, has similar terms to that signed with NHS England (announced on 21 March) with payment weekly in advance, cost recovery and a one month notice period on a rolling basis. The agreement means Spire Healthcare's two hospitals in Wales join the 35 in England assisting the NHS.

We are committed to supporting the NHS in combatting the COVID-19 outbreak and will update the market when further information is available.

For further information please contact:

Registered Office and Head Office:

Spire Healthcare Group plc
3 Dorset Rise
London
EC4Y 8EN

Registered number 09084066

About Spire Healthcare

Spire Healthcare is a leading independent hospital group in the United Kingdom, with 39 private hospitals and 8 clinics across England, Wales and Scotland.

Working in partnership with around 7,300 experienced consultants, Spire Healthcare delivered tailored, personalised care to approximately 810,000 in-patients and daycase patients in 2019, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom.

The Group's well located and scalable hospitals have delivered successful and award-winning clinical outcomes, positioning the Group well with patients, consultants, the NHS, GPs and Private Medical Insurance ("PMI") providers. 85% of Spire Healthcare's hospitals are rated 'Good' or 'Outstanding' by the CQC (or the equivalent in Scotland and Wales).

Spire Healthcare treats patients through a variety of routes including PMI, Self-pay and the NHS, providing the Group with diversified access to the expected growth opportunities in the UK healthcare market, which faces significant supply challenges as a result of NHS budget constraints and increasing demand from a growing population with longer life expectancy.